Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2)

Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2)

Abstract Background Patients with high-frequency episodic migraine (HFEM) have a greater disease burden than those with low-frequency episodic migraine (LFEM). Acute treatment overuse increases the risk of migraine chronification in patients with HFEM. Galcanezumab, a humanized monoclonal antibody b...

Full description

Bibliographic Details
Main Authors: Stephen D. Silberstein, Virginia L. Stauffer, Katie A. Day, Sarah Lipsius, Maria-Carmen Wilson
Format: Article
Language:English
Published: BMC 2019-06-01
Series:The Journal of Headache and Pain
Subjects:
Episodic migraine
Migraine frequency
Galcanezumab
Online Access:http://link.springer.com/article/10.1186/s10194-019-1024-x

Internet

http://link.springer.com/article/10.1186/s10194-019-1024-x

Similar Items